Home > Journals > Journal of Cardiovascular Medicine and Surgery

Journal of Cardiovascular Medicine and Surgery

Submit your article Read this Journals View all journals
Full Text (PDF)
Review Article

Statin Intolerance: Update

Vikram S Patil , Balaraju D , Vikram S Patil , Satvic CM ,

Author Information

Licence:



Journal of Cardiovascular Medicine and Surgery 5(3):p 137-142, July - September 2019. | DOI: http://dx.doi.org/10.21088/jcms.2454.7123.5319.5

How Cite This Article:

Balaraju D, Vikram S Patil, Satvic CM. Statin Intolerance: Update. J Cardiovasc Med Surg. 2019;5(3):137-142.
 

Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Statins are frequently prescribed drugs in cardiology practice. One of the most important causes of nonadherence is mainly because of muscle-related symptoms. The main adverse reactions due to statins include myalgia, myopathy, and new onset diabetes mellitus. Lipophylic statins are more prone to produce myopathy compared to hydrophilic ones. Statins increase the incidence of new onset DM in patients already having risk factors for DM. Therefore statins to be continued rather than discontinuing, if patients are diagnosed with new onset diabetes mellitus. The benefits of statin therapy outweigh the risk. Statin intolerance can be effectively managed either by reducing the dosage, switching to other statin or alternate day statin regimen with rosuvastatin. Non-statin therapies like PCSK-9 inhibitors evolocumab and alirocumab are also optional in high-risk patients who are intolerant to statins or in whom statins are contraindicated. Inclisiran is a promising drug, however long-term safety data is needed. Nutraceuticals have cholesterol lowering activity however there is insufficient evidence with respect to long-term safety and effectivenes.

 

References

No records found.


About this article

Cite this article

Balaraju D, Vikram S Patil, Satvic CM. Statin Intolerance: Update. J Cardiovasc Med Surg. 2019;5(3):137-142.
 

Licence:



Received Accepted Published
N/A N/A N/A
DOI: http://dx.doi.org/10.21088/jcms.2454.7123.5319.5

Keywords

Statin; Side effects; Myopathy; New onset diabetes; Switch therapy; Pcsk 9 inhibitors; Nutraceuticals.

Article Level Metrics

Last Updated

Monday 22 June 2026, 12:22:13 (IST)

681

Accesses

1
121
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received N/A
Accepted N/A
Published N/A

licence




Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share